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Human papillomavirus (HPV) is the main risk factor associated with the development of cervical cancer (CC); however, there
are other factors, such as immunosuppression caused by the human immunodeficiency virus (HIV), that favor progression of
the illness. This study was thus aimed at evaluating the functionality of classical PCR-based molecular tests for the generic iden-
tification of HPVDNA (GP5/GP6, MY09/MY11, and pU1M/2R primers, individually or in combination) using cervical and
urine samples from 194 HIV-positive women. Infected samples were tested with type-specific primers for six high-risk types
(HPV-16, -18, -31, -33, -45, and -58) and two low-risk types (HPV-6 and -11). HPV infection prevalence rates were 70.1% for the
cervical samples and 63.9% for the urine samples. HPV-16 was the most prevalent viral type in the cervical and urine samples,
with higher rates of multiple infections than single infections detected in such samples. HPVDNA detection by PCR (mainly
with the pU1M/2R primer set) in urine samples was positively associated with abnormal cytological findings (atypical squamous
cells of undetermined significance/squamous intraepithelial lesions [ASCUS/SIL]). It was determined that the operative charac-
teristics for detection of cytological abnormalities were similar for cervical and urine samples. This suggested using PCR for the
detection of HPVDNA in urine samples as a potential screening strategy for CC prevention in future prevention and control
programs along with currently implemented strategies for reducing the impact of the disease, i.e., urine samples are economical,
are easy to collect, have wide acceptability among women, and have operative characteristics similar to those of cervical samples.
Cervical cancer (CC) has a great impact on the global femalepopulation, having age-standardized incidence and mortality
rates of 15.2 and 7.8 cases per 100,000 people, respectively (see
http://globocan.iarc.fr). Most new cases occur in developing
countries, where screening programs based primarily on the Pa-
panicolaou (Pap) test are limited by several factors, such as sam-
pling and detection errors (1). In addition to reduced coverage,
the test’s low acceptability among women yields reduced effective-
ness in CC prevention programs (2).
CC patients have usually suffered persistent infections by high-
risk human papillomavirus (HPV) (3); however, most immuno-
competent women (90%) manage to eliminate such viral infec-
tions (4) and spontaneous regression occurs in most cases
(around 60% with low-grade lesions) (5), with this being linked to
the efficiency of a particular female subject’s immune system (6).
In contrast, spontaneous regression rates are considerably re-
duced for immunocompromised women in occasional cases in-
volving HIV coinfection (7), leading to a decline in the number of
CD4 T lymphocytes (8). The probability of elimination of infec-
tion and of lesion regression is low in such populations with high
HPV infection prevalence rates (5).
Strategies aimed at reducing the impact of CC have been im-
plemented for detection of HPV infections before tissue altera-
tions become evident. These strategies, based on detection of DNA
in cervical samples, have led to infected women being identified
and have facilitated their monitoring (9); however, the strategies
are limited by the discomfort involved in sample collection during
gynecological examinations and the requirement for specialized
personnel for sample collection. The potential of such screening
strategies has thus been restricted (10).
Proposed self-sampling from urine constitutes a foundation
for alternative collection methods that are practical, are econom-
ical, and have high acceptability among women (2); even though
this approach usually yields lower cell counts than direct exfolia-
tion sampling methods, it has been reported to be a convenient
screening method, as the viral load in these specimens is associated
with the presence of cervical lesions (11). In addition, using urine
samples could contribute to strengthening screening programs, as
this approach should decrease lesions caused in the cervical epi-
thelial tissue (as with the conventional smear test) and would not
stimulate the natural progression of the illness (i.e., tissue damage
during smear testing facilitates viral entry) (12). HPV DNA detec-
tion in urine samples can be used for screening of at-risk popula-
tions, such as women with compromised immunity (3). This
study was thus aimed at evaluating the HPV infection-detecting
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capacity of classical molecular tests (GP5/GP6, MY09/MY11,
and pU1M/2R primers, used singly or together) with HIV-in-
fected women’s cervical cell samples and self-collected urine sam-
ples, comparing test functionality for identifying viral DNA with
cytological findings.
MATERIALS AND METHODS
Clinical samples.This study included HIV-positive female subjects with a
diagnosis confirmed by Western blotting who were voluntarily attending
the Asistencia Científica de Alta Complejidad S.A.S. CC screening pro-
gram in Bogotá (Colombia). Each woman was informed of the purpose of
the study, signed an informed consent form, and completed a specifically
prepared survey that was used to collect information pertaining to so-
ciodemographic characteristics and related risk factors.
Initial urine midstream sampling involved self-sampling and storage
at 4°C until the samples were processed (within 72 h after collection).
Samples were then taken for conventional cervical Pap testing and for
molecular identification of HPV DNA; the latter samples were then stored
in 95% ethanol as the preservation and transport medium (13). The Pap
tests were performed and interpreted at the Instituto de Diagnóstico
Médico (IDIME); the findings were reported using the Bethesda classifi-
cation system (14). This study was approved and supervised by the ethics
committee of the participating institutions, i.e., the Asistencia Científica
de Alta Complejidad and the Fundación Instituto de Inmunología de
Colombia.
Sample processing. The total volume (around 40 ml) of the urine
samples was centrifuged at 2,300  g for 20 min at 4°C. Cervical sample
cells were taken from the cytobrush, and 50% of the samples were centri-
fuged at 15,000  g for 10 min at 4°C (the other 50% was stored for
inclusion in the cell bank). The cell pellet obtained from each sample
source was subjected to total DNA extraction using a commercial DNA
extraction kit (QuickExtract; Epicentre, Madison, WI), following the
manufacturer’s instructions. Subsequently, DNA sample integrity was
verified by independent PCR amplification of the human -globin gene,
using GH20/PC04 and PC03/PC04 primer sets (15).
HPV detection and type-specific distribution. The positive samples
for amplification of the human -globin gene were subjected to three
simultaneous and independent PCR amplifications. Three sets of primers
previously reported in the literature and evaluated by our group were used
to target two regions of the viral genome for the generic identification of
HPV infection. The first targeted region corresponded to the genes encod-
ing the late viral protein L1. Two primer sets were used for this, i.e.,
GP5/GP6, which is characterized by detecting infections with reduced
viral loads (16), and MY09/MY11, which identifies women infected with
more than one type of HPV (multiple infections) (16). The second tar-
geted region corresponded to the region encoding oncoproteins E6 and
E7, which was targeted using the pU1M/2R primer set; this set has shown
great precision for detecting infections in women with abnormal cytolog-
ical findings in previous studies (17).
The samples that were positive with any of the three generic primer
sets were amplified with type-specific primers for six high-risk types
(HPV-16, -18, -31, -33, -45, and -58) that are linked to85% of CC cases
(18) and two low-risk types (HPV-6 and -11) that are reported to be more
globally prevalent (19). Independently evaluated samples showing an am-
plification product for each type-specific reaction were considered posi-
tive for each viral type. The PCR amplification conditions and controls
used have been reported previously (17, 20). All PCR products were as-
sessed by visualization in 2% agarose gels.
Statistical analysis. Means and standard deviations (SDs) were used
to describe continuous variables; categorical variables were expressed in
terms of frequencies and percentages. The frequencies of events of interest
were reported together with their corresponding 95% confidence inter-
vals (CIs), calculated using the bootstrap method.
Agreement between the results for detecting HPV infection in the two
sample sources was evaluated with kappa coefficients and corresponding
95% confidence intervals. Agreement in the detection of each viral type in
the cervical samples and urine samples was calculated according to the
results of each HPV DNA detection test. The strength of association be-
tween each test result and the variables of interest, such as sociodemo-
graphic characteristics, coinfection, and cytological findings, was mea-
sured using crude odds ratios (ORs) (with corresponding 95% CIs).
The operative characteristics of the cervical and urine sample HPV
tests were evaluated to determine their sensitivities, specificities, positive
predictive values (PPVs), and negative predictive values (NPVs), taking
cytological results as an imperfect gold standard; this adjustment was
based on an algorithm assuming conditional independence (21) and took
previously reported sensitivity (87%) and specificity (66%) values into
account regarding cervical cytology in a population of HIV-infected
women (22). Stata 10 software was used for the statistical analysis.
RESULTS
Fifty-one of the 245 HIV-positive women enrolled were excluded;
18 of the samples collected did not match (the sample from one of
the sources was missing), 23 of the specimens (cervical or urine
specimens) tested negative for amplification of the human -glo-
bin gene, and 10 of the samples were missing or reported unsatis-
factory in Pap test results. A total of 194 paired samples were
included for statistical analysis (mean age, 38.0 years; SD, 10.8
years). In terms of sociodemographic characteristics, most
women (45.4% [n 88] [95% CI, 38.2 to 52.6%]) were34 years
of age, primarily being white (68.4% [n  130] [95% CI, 61.3 to
75.0%]) or of mestizo ethnicity (27.9% [n 53] [95% CI, 21.6 to
34.8%]). Variables related to risk factors showed that 60.8% (n
115) (95% CI, 53.5 to 63.8%) of the women had started sexual
activity before the age of 18 years, 36.7% (n 69) (95% CI, 29.8 to
44.0%) stated that they had had four or more sexual partners, and
the most widely used contraceptive method was the barrier
method, being used by 32.9% (n 52) (95% CI, 25.7 to 40.8%) of
the women.
The rates of HPV infection prevalence (defined as samples hav-
ing a positive result with any of the three primer sets evaluated, i.e.,
GP5/GP6, MY09/MY11, and/or pU1M2R) were 70.1% (n 
136) (95% CI, 63.4 to 76.8%) in cervical samples and 63.9% (n
124) (95% CI, 56.9 to 70.9%) in urine samples, with greater pos-
itivity frequency being found in the cervical samples than in the
urine samples; this difference was statistically significant (2 [1
degree of freedom] 6.9486; P 0.008). Table 1 describes HPV
infection frequencies for both sample sources according to so-
ciodemographic and risk factor categorization.
Single and multiple (simultaneous infection by more than one
type of HPV) infection frequencies were defined. The overall sin-
gle infection prevalence rates were 19.6% (n 38) (95% CI, 14.2
to 25.9%) for cervical samples and 25.8% (n 50) (95% CI, 19.8
to 32.6%) for urine samples. These rates were lower than multiple
infection prevalence rates, i.e., 54.6% (n 106) (95% CI, 47.4 to
61.8%) in cervical samples and 40.2% (n 78) (95% CI, 33.2 to
47.5%) in urine samples. The rates of multiple infections for cer-
vical and urine samples were not statistically significantly different
(2 [1] 0.0126; P 0.911).
The distribution of PCR results for generic identification of
HPV DNA and type-specific identification considering the pres-
ence of any of the three infection levels (none, single, or multiple)
is detailed in Table 2. The percentages of HPV DNA detection
were similar for all primer sets. It was found that HPV-16 was the
most prevalent viral type in both cervical and urine samples. How-
ever, the distributions of HPV of the remaining types were differ-
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ent between sample sources. It was also noted that all HPV types
tested in the population were found more frequently in multiple
infections for both sample sources.
The results showed associations between HPV DNA detection
for both cervical and urine samples and the presence of multiple
infections. This was determined with OR values for association
with positive GP5/GP6 results of 8.1 (95% CI, 3.8 to 17.2) for
cervical samples and 3.7 (95% CI, 1.9 to 7.0) for urine samples and
values for association with positive MY09/MY11 results of 7.0
(95% CI, 3.4 to 14.4) for cervical samples and 5.0 (95% CI, 2.5 to
9.8) for urine samples. The strongest association was found with
pU1M/2R, for which the adjusted OR values were 12.5 (95% CI,
5.2 to 30.1) for cervical samples and 6.7 (95% CI, 3.2 to 14.0) for
urine samples. All associations were statistically significant (P 
0.000).
The overall agreement between the molecular detection of
HPV infection in cervical and urine samples was 63.9% ( 0.18
[95% CI, 0.05 to 0.33]). Table 3 shows the agreement obtained for
the six HPV types evaluated in both types of samples according to
their detection by the three HPV DNA detection tests (GP5/
GP6, MY09/MY11, and/or pU1M2R). The frequency of cyto-
logical abnormalities in the analyzed population was 28.9% (n
56) (95% CI, 22.6 to 35.8%); 35.7% (n  20) (95% CI, 23.4 to
49.6%) of those subjects were classified as having atypical squa-
mous cells of undetermined significance (ASCUS), 57.2% (n 
32) (95% CI, 43.2 to 70.3%) had low-grade squamous intraepi-
thelial lesions (LSILs), and 7.1% (n  4) (95% CI, 1.9 to 17.3%)
had high-grade squamous intraepithelial lesions (HSILs).
Table 4 describes the molecular test results for each sample
source according to the Pap test report. An association was found
between HPV infection in urine samples and LSIL findings, with
HPV infection being 4.0-fold (95% CI, 1.4- to 11.4-fold) more
frequent in women with this type of abnormality. No association
was found for the cervical samples. The only association found in
evaluations of the results for each primer set (conducted indepen-
dently) in urine samples was between positive pU1M/2R results
and LSIL findings (OR, 2.8 [95% CI, 1.3 to 6.4]).
The operative characteristics were adjusted by bearing in mind
the presence of an imperfect gold standard; cervical cytological
findings were considered positive when ASCUS, LSILs, or HSILs
were identified (Bethesda classification system) (14). It was found
that urine samples had a sensitivity of 68.6% (95% CI, 58.7 to
74.5%), a specificity of 21.2% (95% CI, 10.7 to 32.8%), a positive
predictive value (PPV) of 68.0% (95% CI, 59.7 to 75.7%), and a
negative predictive value (NPV) of 20.1% (95% CI, 10.2 to
31.6%). Cervical samples had a sensitivity of 57.2% (95% CI, 48.8
to 65.6%), a specificity of 19.1% (95% CI, 48.8 to 65.6%), a PPV of
64.0% (95% CI, 55.4 to 72.2%), and an NPV of 15.1% (95% CI,
6.9 to 24.1%). All urine sample tests had characteristics very sim-
ilar to those of cervical sample tests (see Table S1 in the supple-
mental material).
Table 5 presents positivity rates for the generic and type-spe-
cific tests, stratified by cytological findings. The stratification re-
sults (according to the cytological findings) showed that the tests
detected HPV DNA with greater frequency in women with abnor-
mal cytology findings.
DISCUSSION
Considering the role of HPV infection in the development of CC,
viral DNA detection has become an important tool for screening
at-risk populations (9). The available evidence shows higher HPV
infection rates in the presence of immunosuppression caused by
HIV than in the general population (80 to 90% versus 22 to 50%),
a reduction of low-grade lesion regression rates (27% versus
60%), and a reduction in the time required for the disease to
develop (5).
Current screening techniques for detecting HPV DNA have
used alternative sample sources (tampon-type devices, self-sam-
pling of vaginal smears, and self-sampled urine) to facilitate inclu-
TABLE 1 Sociodemographic characteristics and HPV positivity
regarding the population being studied according to cervical and urine
sample results
Characteristica
Total no.
(%)
HPV infection in:
Cervical samples Urine samples
n (%) P n (%) P
Age (n 194)
20–34 yr 88 (45.4) 65 (73.9) 0.053 54 (61.4) 0.038
35–49 yr 70 (36.1) 42 (60.0) 52 (74.3)
50 yr 36 (18.5) 29 (80.6) 18 (50.0)
Ethnicity (n 190)
White 130 (68.4) 91 (70.0) 0.990 80 (61.5) 0.444
Indigenous 3 (1.6) 2 (66.7) 2 (66.7)
Mestizo 53 (27.9) 38 (71.7) 35 (66.0)
Black 4 (2.1) 3 (75.0) 4 (100.0)
Age at first intercourse
(n 190)
18 yr 115 (60.9) 83 (72.2) 0.631 71 (61.7) 0.533
18 yr 74 (39.1) 51 (68.9) 49 (66.2)
Lifetime no. of sexual
partners (n 188)
1 30 (16.0) 21 (70.0) 0.997 20 (66.7) 0.914
2 46 (24.4) 33 (71.7) 28 (60.9)
3 43 (22.9) 30 (69.8) 26 (60.5)
4 69 (36.7) 49 (71.0) 45 (65.2)
Contraceptive method
(n 158)
None 32 (20.3) 20 (62.5) 0.029 19 (59.4) 0.252
Hormonal 5 (3.1) 3 (60.0) 2 (40.0)
Barrier 68 (43.0) 54 (79.4) 43 (63.2)
Barrier plus hormonal 3 (1.9) 0 (0.0) 3 (100.0)
Barrier plus other 18 (11.4) 10 (55.6) 10 (55.6)
Surgery 32 (20.3) 22 (68.7) 25 (78.1)
Cigarette smoking
(n 187)
No 159 (85.0) 112 (70.5) 0.379 103 (64.8) 0.960
Yes 28 (15.0) 22 (78.6) 18 (64.3)
Pregnancies (n 192)
None 9 (4.8) 6 (66.7) 0.935 7 (77.8) 0.087
1 45 (24.2) 32 (71.1) 27 (60.0)
2 47 (25.3) 31 (66.0) 36 (76.6)
3 46 (24.7) 34 (73.9) 23 (50.0)
4 39 (21.0) 28 (71.8) 25 (64.1)
a Categories involved less than 194 women, given that data were missing from the
surveys. HPV infection was considered positive when the PCR results using any of the
three primer sets (GP5/GP6, MY09/11, and/or pU1M2R) were positive. P values
correspond to sampling distribution probabilities of chi-square distributions.
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sion of greater numbers of women. Among the various sampling
sources available, urine has been considered an economical and
easily obtained source for sampling; it has been widely used for
detection of other sexually transmitted infections (3), and detec-
tion of HPV DNA in self-collected urine samples could facilitate
the inclusion of women in regions where gynecological screening
coverage is low (23).
This study (the first held in Colombia regarding the frequency
of HPV-HIV coinfection) has described infection prevalence re-
garding HPV detection in cervical and urine samples, and the
results showed prevalence rates for both sample sources similar to
the data reported in previous studies (24, 25). The urine samples
had lower DNA prevalence than the cervical samples; this could
have been related to the biological characteristics of the sample
sources, since the samples were not derived from the original site
of infection (10). It also may have been related to technical char-
acteristics related to the urine samples, such as contaminants, PCR
inhibitors, certain intake conditions, or storage and processing,
which also could have affected amplification (12). However, the
results obtained in this study support using urine samples for
identification of HPV DNA since such samples were generally
comparable to cervical samples, which are widely used for HPV
detection.
The use of barrier contraceptives has been reported in previous
studies as a strategy for the primary prevention of preneoplastic
lesions (26). However, the results obtained in this study showed an
association between the risk of HPV infection and the use of these
contraceptives. These results could be related to lifestyle charac-
teristics, mainly sexual habits, which would favor HPV infection
being acquired (27).
HPV DNA detection was favored by the methodological design
implemented in this study using three primer sets, as recorded
previously; this contributed to making the epidemiological study
more robust (16) and facilitated viral DNA detection in a greater
number of women. A higher percentage of single infections was
detected in urine samples; this could have been related to the
normal course of persistent infection involving an increase in the
number of viral copies and the start of a cell differentiation pro-
gram in which one cell layer gradually replaces another (i.e., meta-
plasia) (28). Such replacement could facilitate cervical cells ap-
pearing in urine.
Regarding type-specific viral distribution, it was observed that
HPV-16 was the most prevalent in both types of samples, which
was consistent with previously reported data for both the general
population (20, 29) and the HIV-positive population (30). The
distributions of the other tested HPV types varied between the two
sample sources, which could have been due to different affinities
of some viral types for particular types of epithelium (keratinized
or not) (31) or the fact that certain HPV types commonly infect
TABLE 2 Results of generic HPV detection and type-specific distribution for cervical and urine samples
Analysis
Results (n [%]) fora:
Cervical samples Urine samples
Without
infection
Single
infection
Multiple
infection
Without
infection
Single
infection
Multiple
infection
Generic HPV DNA detectionb
GP5/GP6 110 (56.7) 16 (8.2) 68 (35.1) 126 (65.0) 27 (13.9) 41 (21.1)
MY09/11 108 (55.7) 18 (9.2) 68 (35.1) 122 (62.9) 26 (13.4) 46 (23.7)
pU1M/2R 115 (59.3) 11 (5.6) 68 (35.1) 133 (68.5) 18 (9.3) 43 (22.2)
Type-specific distributionc
HPV-16 46 (33.8) 11 (8.1) 79 (58.1) 48 (38.7) 21 (16.9) 55 (44.4)
HPV-18 79 (58.1) 4 (2.9) 53 (39.0) 83 (66.9) 4 (3.2) 37 (29.9)
HPV-31 72 (52.9) 6 (4.4) 58 (42.7) 86 (69.4) 3 (2.4) 35 (28.2)
HPV-33 96 (70.6) 1 (0.7) 39 (28.7) 100 (80.7) 2 (1.6) 22 (17.7)
HPV-45 121 (89.0) 2 (1.4) 13 (9.6) 101 (81.5) 6 (4.8) 17 (13.7)
HPV-58 97 (71.3) 4 (2.9) 35 (25.8) 79 (63.7) 7 (5.7) 38 (30.6)
a Percentages were calculated by rows for each sample source.
b The total number of samples for generic HPV DNA detection was 194.
c The total numbers of samples included in the type-specific distribution analyses were 136 for the cervical samples and 124 for the urine samples. Type-specific identification was
determined by independent PCRs using type-specific primer sets.
TABLE 3 Agreement in the detection of each viral type in cervical and
urine samples according to the results of HPV DNA detection tests
HPV DNA
detection test
HPV
type
Agreement
(%) Kappa (95% CI)
GP5/GP6 HPV-16 63.4 0.030 (	0.111 to 0.171)
HPV-18 75.3 	0.024 (	0.152 to 0.104)
HPV-31 71.1 	0.004 (	0.134 to 0.127)
HPV-33 87.6 0.141 (	0.056 to 0.338)
HPV-45 88.1 	0.063 (	0.106 to	0.020)
HPV-58 80.9 0.136 (	0.038 to 0.310)
MY09/11 HPV-16 65.0 0.074 (	0.072 to 0.219)
HPV-18 74.2 	0.064 (	0.175 to 0.047)
HPV-31 72.7 0.017 (	0.117 to 0.150)
HPV-33 80.9 0.164 (	0.017 to 0.346)
HPV-45 86.6 	0.068 (	0.112 to	0.023)
HPV-58 76.3 	0.019 (	0.152 to 0.113)
pU1M/2R HPV-16 63.9 	0.005 (	0.143 to 0.132)
HPV-18 78.4 0.135 (	0.026 to 0.296)
HPV-31 74.2 0.059 (	0.084 to 0.202)
HPV-33 83.5 0.110 (	0.067 to 0.288)
HPV-45 92.3 0.077 (	0.139 to 0.293)
HPV-58 78.4 0.036 (	0.116 to 0.188)
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the lower reproductive tract (32), which favors their detection in
urine samples.
The association found between the detection of viral infections
in urine samples using PCRs (in combination) and the pU1M/2R
primer set and abnormal cytological findings supported the use of
this sample source in screening tests. This methodology has ad-
vantages, such as convenience regarding sample collection, low
costs, and greater acceptability among women (12). It also sug-
gests the usefulness of this sample source in identifying women at
risk of developing precancerous lesions, consistent with previous
reports (17).
In spite of relatively good agreement between the detection
of each viral type in cervical and urine samples according to the
results of each HPV DNA detection test, the kappa values were
extremely low. This finding could have been due to the paradoxical
relationship between kappa values and agreement (as proposed for
this type of study), which is dramatically affected by trait prevalence
in the population being considered (33), in this case the high fre-
quency of infection found in both sample sources.
The operative characteristics of the tests from the two sample
sources led to low results. However, it should be noted, regarding
diagnostic performance, that cervical cytological data represent an
imperfect gold standard; this could be related to the presence of
disease, not the infection, and what is ultimately determined by
molecular testing. In spite of this, the tests had similar results with
the two sample sources, supporting the use of urine samples for
the molecular identification of HPV DNA, since such samples
have sensitivity comparable to that found in a prior study for
TABLE 4 Associations between HPV DNA detection in the two types of samples and cytological results
Cytological resultsa Sample
No. (%) of samples with HPV DNA
detected using:
No. (%) of
samples
with HPV
infectiond
Crude odds ratio (95% CI) for detection results
using:
Crude odds
ratio (95% CI)
for HPV
infectiondGP5/GP6 MY09/11 pU1M/2R GP5/GP6 MY09/11 pU1M/2R
Normal (n 138) Cervical 49 (35.5) 53 (38.4) 50 (36.2) 92 (66.7) 1.0 1.0 1.0 1.0
Urine 44 (31.9) 50 (36.2) 36 (26.1) 79 (57.2) 1.0 1.0 1.0 1.0
ASCUS (n 20) Cervical 13 (65.0) 12 (60.0) 10 (50.0) 16 (80.0) 3.4 (1.2–9.2)b 2.4 (0.9–6.4) 1.8 (0.7–4.6) 2.0 (0.6–6.4)
Urine 9 (45.0) 10 (50.0) 7 (35.0) 15 (75.0) 1.7 (0.7–4.6) 1.8 (0.7–4.6) 1.5 (0.6–4.1) 2.2 (0.8–6.6)
LSIL (n 32) Cervical 19 (59.4) 21 (65.6) 17 (53.1) 25 (78.1) 2.7 (1.2–5.9)b 3.1 (1.3–7.0)b 2.0 (0.9–4.4) 1.8 (0.7–4.5)
Urine 14 (43.8) 11 (34.4) 16 (50.0) 27 (84.4) 1.7 (0.8–3.7) 0.9 (0.4–2.1) 2.8 (1.3–6.4)b 4.0 (1.4–11.4)b
HSIL (n 4) Cervical 3 (75.0) 0 (0.0) 2 (50.0) 3 (75.0) 5.4 (0.5–55.4) 0.0 (NC)c 1.8 (0.2–13.0) 1.5 (0.2–14.9)
Urine 1 (25.0) 1 (25.0) 2 (50.0) 3 (75.0) 0.7 (0.1–7.1) 0.6 (0.1–5.8) 2.8 (0.4–21.2) 2.2 (0.2–22.4)
a ASCUS, atypical squamous cells of undetermined significance; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.
b Statistically significant.
c NC, not calculable. The estimator could not be calculated because one of the fields contained no data during the dispersion analysis.
d HPV infection was considered positive when the PCR results using any of the three primer sets were positive.
TABLE 5 Molecular test positivity for detection of HPV infection, stratified by cytological findings
Analysis
HPV DNA detection
test or HPV type Sample
No. (%) with positive results and cytological findings of:
Normal ASCUS LSIL HSIL
Generic HPV DNA detection (n 194) HPV infectiona Cervical 92 (66.7) 16 (80.0) 25 (78.1) 3 (75.0)
Urine 79 (57.2) 15 (75.0) 27 (84.4) 3 (75.0)
GP5/GP6 Cervical 49 (35.5) 13 (65.0) 19 (59.4) 3 (75.0)
Urine 44 (31.9) 9 (45.0) 14 (43.8) 1 (25.0)
MY09/11 Cervical 53 (38.4) 12 (60.0) 21 (65.6) 0 (0.0)
Urine 50 (36.2) 10 (50.0) 11 (38.4) 1 (25.0)
pU1M/2R Cervical 50 (36.2) 10 (50.0) 17 (53.1) 2 (50.0)
Urine 36 (26.1) 7 (35.0) 16 (50.0) 2 (50.0)
Type-specific distributionb HPV-16 Cervical 64 (69.6) 9 (56.3) 14 (56.0) 17 (60.7)
Urine 45 (57.0) 9 (60.0) 3 (100.0) 22 (73.3)
HPV-18 Cervical 39 (42.4) 2 (12.5) 16 (56.0) 2 (66.7)
Urine 25 (31.7) 8 (53.3) 7 (25.9) 1 (33.3)
HPV-31 Cervical 38 (41.3) 8 (50.0) 17 (60.0) 1 (33.3)
Urine 24 (30.4) 7 (46.7) 7 (25.9) 0 (0.0)
HPV-33 Cervical 24 (26.1) 3 (18.8) 12 (48.0) 1 (33.3)
Urine 16 (20.3) 2 (13.3) 5 (18.5) 1 (33.3)
HPV-45 Cervical 7 (7.6) 3 (18.8) 5 (20.0) 0 (0.0)
Urine 12 (15.2) 5 (33.3) 5 (18.5) 1 (33.3)
HPV-58 Cervical 24 (26.1) 3 (18.8) 11 (44.0) 1 (33.3)
Urine 26 (32.9) 6 (40.0) 11 (40.7) 2 (66.7)
a HPV infection was considered positive when the PCR results using any of the three primer sets were positive.
b Categories involved less than 194 women, given that only women identified as being infected with HPV were included in the type-specific identification reactions, meaning that n
values for each diagnostic category varied for the HPV types. Type-specific identification was determined by independent PCRs using type-specific primer sets.
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molecular detection in cervical samples obtained from a general
population (17). Future studies should involve the development
of urine sample validation for detection of HPV DNA.
Even though the samples did not come directly from the viral
infection site, there are valid reasons for using urine as a potential
alternative for detection of HPV DNA, such as the proximity of the
lower urinary tract to the vagina, vulva, and cervix and the suscepti-
bility of the bladder epithelium to HPV infection. It has been sug-
gested that the main source of viral DNA could be contamination by
desquamated cells and that the amount of viral DNA in urine could
be related to the amount of epithelial cells and the viral load (34).
The data reported in this study have suggested the use of mo-
lecular tests not only with directly derived cervical tissue samples
but also with self-collected samples such as urine samples. Our
results showed that this sample source was useful for identifying
women with abnormal cytological findings and presented opera-
tive characteristics similar to those found for cervical samples. The
intrinsic characteristics (ease of collection, low cost, and greater
acceptability by the female population) of urine samples indicated
that such samples might be included in future routine screening
tests, especially in developing countries where CC rates are high.
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